InsidersTradesSigma
Follow the NATERA, INC stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €47bn. The latest transaction was filed on 12 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MATTHEW RABINOWITZ. The full history is accessible without an account.
Analysts rate NATERA, INC Strong Buy (bullish), based on 21 analysts. Average price target: US$336.74.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Natera, Inc 是一家专注于基因诊断和健康检测的公司。它为生殖健康和遗传疾病管理提供解决方案。